Canadian Perspective on Overall survival (OS) in KATE2.

Regarder maintenant Canadian Perspective on Overall survival (OS) in KATE2.

KEYNOTE-119: Phase 3 study of pembrolizumab versus single-agent chemotherapy for metastatic triple-negative breast cancer.

Regarder maintenant KEYNOTE-119: Phase 3 study of pembrolizumab versus single-agent chemotherapy for metastatic triple-negative breast cancer.

Message from our Editor-in-Chief

Regarder maintenant Message from our Editor-in-Chief

Message from our Scientific Editor

Regarder maintenant Message from our Scientific Editor

Identifying Research Priorities in Prediction of Response in Patients with Early Breast Cancer

Regarder maintenant Identifying Research Priorities in Prediction of Response in Patients with Early Breast Cancer